BSN CAPITAL PARTNERS Ltd Invests $50.15 Million in Boston Scientific Corporation $BSX

BSN CAPITAL PARTNERS Ltd bought a new stake in shares of Boston Scientific Corporation (NYSE:BSX) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 500,000 shares of the medical equipment provider’s stock, valued at approximately $50,150,000. Boston Scientific accounts for 2.2% of BSN CAPITAL PARTNERS Ltd’s portfolio, making the stock its 11th biggest position.

Several other institutional investors have also modified their holdings of the business. Norges Bank acquired a new position in Boston Scientific during the 4th quarter worth $2,199,395,000. Egerton Capital UK LLP raised its holdings in Boston Scientific by 223.7% during the third quarter. Egerton Capital UK LLP now owns 5,312,504 shares of the medical equipment provider’s stock worth $518,660,000 after purchasing an additional 3,671,548 shares in the last quarter. Maverick Capital Ltd. acquired a new stake in Boston Scientific during the 4th quarter worth $280,735,000. Farallon Capital Management LLC increased its position in shares of Boston Scientific by 56.7% during the fourth quarter. Farallon Capital Management LLC now owns 7,439,564 shares of the medical equipment provider’s stock worth $709,362,000 after purchasing an additional 2,693,007 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership lifted its stake in Boston Scientific by 31.9% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 11,035,628 shares of the medical equipment provider’s stock valued at $1,052,247,000 after buying an additional 2,668,230 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Price Performance

NYSE BSX opened at $45.30 on Friday. The stock has a market capitalization of $67.33 billion, a PE ratio of 18.95, a price-to-earnings-growth ratio of 0.87 and a beta of 0.56. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42. The company has a 50 day moving average price of $54.71 and a two-hundred day moving average price of $73.03. Boston Scientific Corporation has a 12-month low of $44.44 and a 12-month high of $109.50.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The company had revenue of $5.20 billion during the quarter, compared to analysts’ expectations of $5.19 billion. During the same period in the prior year, the business earned $0.75 earnings per share. Boston Scientific’s revenue for the quarter was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, equities analysts predict that Boston Scientific Corporation will post 3.36 earnings per share for the current fiscal year.

Boston Scientific announced that its board has initiated a share buyback plan on Monday, May 18th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical equipment provider to purchase up to 6.4% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s leadership believes its shares are undervalued.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on BSX shares. The Goldman Sachs Group set a $71.00 price target on Boston Scientific in a report on Thursday, May 28th. Wolfe Research cut Boston Scientific from an “outperform” rating to a “peer perform” rating in a research report on Friday, May 29th. Canaccord Genuity Group cut their price target on Boston Scientific from $71.00 to $70.00 and set a “buy” rating for the company in a report on Monday, June 1st. Argus raised Boston Scientific to a “strong-buy” rating in a research report on Thursday, February 26th. Finally, Robert W. Baird set a $70.00 price objective on shares of Boston Scientific in a report on Thursday, May 28th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $85.08.

Insider Buying and Selling at Boston Scientific

In other news, Director David C. Habiger purchased 2,250 shares of the business’s stock in a transaction dated Wednesday, May 20th. The shares were acquired at an average price of $55.92 per share, with a total value of $125,820.00. Following the completion of the purchase, the director directly owned 13,878 shares of the company’s stock, valued at $776,057.76. The trade was a 19.35% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Cheryl Pegus acquired 1,770 shares of the company’s stock in a transaction on Wednesday, May 20th. The shares were purchased at an average cost of $56.49 per share, with a total value of $99,987.30. Following the completion of the acquisition, the director directly owned 1,770 shares in the company, valued at approximately $99,987.30. The trade was a ? increase in their position. The SEC filing for this purchase provides additional information. In the last quarter, insiders acquired 9,800 shares of company stock worth $554,012. 0.34% of the stock is currently owned by insiders.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.